Mainz Biomed N.V. Files 20-F Annual Report for Fiscal Year Ended December 31, 2023

TL;DR

<b>Mainz Biomed N.V. has filed its 2023 annual report on Form 20-F, detailing its financial performance and corporate status.</b>

AI Summary

MAINZ BIOMED N.V. (MYNZ) filed a Foreign Annual Report (20-F) with the SEC on April 9, 2024. Mainz Biomed N.V. filed its annual report on Form 20-F for the fiscal year ended December 31, 2023. The company's ordinary shares trade on The Nasdaq Stock Market LLC under the symbol MYNZ. As of December 31, 2023, there were 21,165,482 ordinary shares outstanding. The filing indicates that Mainz Biomed N.V. is not a well-known seasoned issuer. The company is incorporated in The Netherlands and its principal executive offices are located in Mainz, Germany.

Why It Matters

For investors and stakeholders tracking MAINZ BIOMED N.V., this filing contains several important signals. This filing provides investors with a comprehensive overview of the company's operations and financial health for the past fiscal year, crucial for investment decisions. The 20-F report is a mandatory filing for foreign private issuers like Mainz Biomed N.V., ensuring transparency and compliance with SEC regulations.

Risk Assessment

Risk Level: low — MAINZ BIOMED N.V. shows low risk based on this filing. The filing is a standard annual report (20-F) and does not contain new or significant financial disclosures that would alter the risk profile.

Analyst Insight

Review the full 20-F filing to understand Mainz Biomed N.V.'s financial performance, operational highlights, and any disclosed risks for the fiscal year 2023.

Key Numbers

• 21,165,482 — Outstanding Ordinary Shares (As of December 31, 2023)
• 2023-12-31 — Fiscal Year End (Report period)
• 2024-04-09 — Filing Date (Date of submission)

Key Players & Entities

• MAINZ BIOMED N.V. (company) — Registrant
• MYNZ (company) — Trading symbol
• The Nasdaq Stock Market LLC (company) — Exchange
• Guido Baechler (person) — Chief Executive Officer
• 2023-12-31 (date) — Fiscal year end
• 2024-04-09 (date) — Filing date
• 21,165,482 (dollar_amount) — Outstanding ordinary shares

FAQ

Industry Context

Mainz Biomed N.V. operates in the pharmaceutical preparations industry, focusing on the development and commercialization of diagnostic tests.

Regulatory Implications

As a foreign private issuer, Mainz Biomed N.V. is subject to SEC regulations, including the requirement to file annual reports on Form 20-F.

What Investors Should Do

1. Analyze the financial statements within the 20-F for revenue, expenses, and cash flow.
2. Review the business overview section for strategic updates and product pipeline information.
3. Examine any disclosed risk factors or legal proceedings mentioned in the report.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 20-F filing.
• 2024-04-09: Filing Date — Date the 20-F annual report was submitted to the SEC.

Year-Over-Year Comparison

This is the annual report for the fiscal year ended December 31, 2023, following previous filings by Mainz Biomed N.V.

Key Financial Figures

• $26,295,727 — nd December 31, 2022 were approximately $26,295,727 and $26,387,336, respectively. Ultimate
• $26,387,336 — 2022 were approximately $26,295,727 and $26,387,336, respectively. Ultimately, our ability
• $4.6 million — and development (where the approximate $4.6 million increase in our research and developmen
• $69,328,021 — ng losses, accumulated deficit totaling $69,328,021 and negative cash flows used in operati
• $21,938,845 — h flows used in operating activities of $21,938,845 as of and for the year ended December 3

Filing Documents

• ea0203354-20f_mainz.htm (20-F) — 2217KB
• ea020335401ex11-1_mainz.htm (EX-11.1) — 41KB
• ea020335401ex12-1_mainz.htm (EX-12.1) — 9KB
• ea020335401ex12-2_mainz.htm (EX-12.2) — 9KB
• ea020335401ex13-1_mainz.htm (EX-13.1) — 5KB
• ea020335401ex15-1_mainz.htm (EX-15.1) — 3KB
• ea020335401ex97-1_mainz.htm (EX-97.1) — 37KB
• image_001.jpg (GRAPHIC) — 7KB
• image_002.jpg (GRAPHIC) — 13KB
• image_004.jpg (GRAPHIC) — 17KB
• image_003.jpg (GRAPHIC) — 12KB
• 0001213900-24-031299.txt (&nbsp;) — 9608KB
• mynz-20231231.xsd (EX-101.SCH) — 137KB
• mynz-20231231_cal.xml (EX-101.CAL) — 51KB
• mynz-20231231_def.xml (EX-101.DEF) — 394KB
• mynz-20231231_lab.xml (EX-101.LAB) — 808KB
• mynz-20231231_pre.xml (EX-101.PRE) — 417KB
• ea0203354-20f_mainz_htm.xml (XML) — 1415KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F REGISTRATION OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ OR SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report _______________ Commission file number 001-41010 Mainz Biomed N.V. (Exact name of Registrant specified in its charter) Not Applicable (Translation of Registrant's name into English) The Netherlands (Jurisdiction of incorporation or organization) Mainz Biomed N.V . Robert Koch Strasse 50 55129 Mainz Germany (Address of principal executive offices) Mr. Guido Baechler Chief Executive Officer +49 (0) 6131 / 55428-60 info@mainzbiomed.com (Name, Telephone, Email and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act. Title of Each Class Trading symbol(s) Name of each exchange on which registered Ordinary Shares MYNZ The Nasdaq Stock Market LLC Securities registered or to be registered pursuant to Section 12(g) of the Act. None (Title of Class) Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. Ordinary Shares (Title of Class) Number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of business of the period covered by the annual report. 21,165,482 Ordinary Shares Indicate b y check mark if the Registrant is a well-known seasoned issuer as defined in Rule 405 of the Securities Act. Yes No If this report is an annual or transition report, indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Yes No Indicate by check mark whether Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically on its corporate Web site, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of "accelerated filer," "large accelerated filer," and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large Accelerated Filer Accelerated Filer Non Accelerated Filer Emerging Growth Company If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to 240.10D-1(b). Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing: U.S. GAAP International Financial Reporting Standards as issued Other by the International Accounting Standards Board If "Other" has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow: Item 17 Item 18 If this is an annual report, indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b 2 of the Exchange Act): Yes No (APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS)

View Full Filing

View this 20-F filing on SEC EDGAR